No Data
No Data
No Data
No Data
No Data
EDIT, CLNE and NIU Are Among After Hour Movers
Seeking AlphaApr 26 17:00 ET
Cabaletta Bio Is Maintained at Buy by Citigroup
Cabaletta Bio Is Maintained at Buy by Citigroup
Dow JonesApr 4 11:57 ET
Express News | Citigroup Maintains Buy on Cabaletta Bio, Raises Price Target to $30
Moomoo 24/7Apr 4 11:47 ET
Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and Cabaletta Bio (CABA)
TipRanksApr 4 05:20 ET
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), HilleVax, Inc (HLVX) and Cabaletta Bio (CABA)
TipRanksMar 25 22:10 ET
Cabaletta Bio Issued ID#NCT06328777 For Phase 1/2 Open-Label Study To Evaluate The Safety And Efficacy Of CABA-201, A CD19-CAR T Cell Therapy, In Subjects With Systemic Sclerosis Posted To Clinical Trials Website On 2024-03-25
Inclusion Criteria:Age ≥18 and ≤70A clinical diagnosis of SSc, based on the 2013 American College of Rheumatology and European League Against Rheumatism classification criteria.Early active diseaseEvi
BenzingaMar 25 10:25 ET
Alex Vrublevskiy : Hi Amy
Alex Vrublevskiy : AMY ARE YIU IN Bntc?
AmyNicOP Alex Vrublevskiy: No
Alex Vrublevskiy : )
Alvinnnnnnngenius : Wtf this thing keep going 0.59 to 14
No Data
No Data
diamonds : 请问,ENDPQ重组后,持有的股票还能有效吗?